Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects

Journal of Clinical Investigation

Volumn 100, Issue 11, 1997, Pages 2737-2743

  De Paoli, Paolo ^a   Zanussi, Stefania ^a   Simonelli, Cecilia ^a   Bortolin, Maria Teresa ^a   D'Andrea, Monica ^a   Crepaldi, Cinzia ^a   Talamini, Renato ^a   Comar, Manola ^b   Giacca, Mauro ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

CD4 positive T lymphocytes; Cytokines; HIV infection; HIV viremia; Interleukin 2 injections

Indexed keywords

CD28 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DIDANOSINE; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RANTES; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE ANTIGEN; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; VIREMIA;

EID: 0031439413     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119819     Document Type: Article

References (45)

1. Clerici, M., and G. Shearer. 1994. Th1-Th2 hypothesis in HIV infection: new insights. Immunol. Today. 15:575-581.
2. Clerici, M., C. Balotta, A. Salvaggio, C. Riva, D. Trabattoni, L. Papagno, A. Berlusconi, S. Rusconi, M.L. Villa, M. Moroni, and M. Galli. 1996. Human Immunodeficiency Virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood. 2:574-579.
3. Rosemberg, L.F., and A.S. Fauci. 1990. Immunopathogenetic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol. Today. 11:176-180.
4. Romagnani, S., E. Maggio, and G. Del Prete. 1994. An alternative view of the Th1/fh2 switch hypothesis in HIV infection. AIDS Res. Hum. Retroviruses. 10:3-9.
5. Mosmann, T.R., and S. Subash. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:138-146.
6. Fan, J., H.Z. Bass, and J.L. Fahey. 1993. Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J. Immunol. 151:5031-5040.
7. Adachi, Y., N. Oyaizu, S. Than, T.W. McCloskey, and S. Pahwa. 1996. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. J. Immunol. 157:4184-4193.
8. Loetscher, P., M. Seitz, M. Baggiolini, and B. Moser. 1996. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184:569-577.
9. Wu, L., W.A. Paxton, N. Kassam, N. Ruffing, J.B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R.A. Koup, and C.R. Mackay. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro. J. Exp. Med. 185:1681-1691.
10. Premack, B.A., and T.J. Schall. 1996. Chemokine receptors: gateways to inflammation and infection. Nat. Med. 2:1174-1178.
11. Cocchi, F., A.L. DeVico, A. Garzino-Demo, S.K. Arya, R.C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1, and MIP-1 as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1811-1816.
12. D'Souza, M.P., and V.A. Harden. 1996. Chemokines and HIV-1 second receptors. Nat. Med. 2:1293-1300.
13. Moore, J.P. 1997. Coreceptors: implications for HIV pathogenesis and therapy. Science. 276:51-52.
14. Clerici, M., E. Roilides, K.M. Butler, L. DePalma, D. Venzon, G.N. Shearer, and P.A. Pizzo. 1992. Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood. 80:2196-2202.
15. Emery, S., and H.C. Lane. 1996. Immune-based therapies in HIV infection: recent developments. AIDS (Lond.). 10:159-163.
16. Teppler, H., G. Kaplan, K.A. Smith, A.L. Montana, P. Meyn, and Z.A. Cohn. 1993. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 177:483-492.
17. Leef Jacobson, E., F. Pilaro, and K.A. Smith. 1996. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA. 93:10405-10410.
18. Kovacs, J.A., S. Vogel, J.M. Albert, J. Fallon, R.T. Davey, R.E. Walker, M.A. Polis, K. Spooner, J.A. Metcalf, M. Baseler, et al. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350-1356.
19. Connors, M., J.A Kovacs, S. Krevat, J.C. Gea-Banacloche, M.C. Sneller, M. Flanigan, J.A. Metcalf, R.E. Walker, J. Falloon, M. Baseler, et al. 1997. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3:533-540.
20. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR (Morb. Mortal. Wkly. Rep.). 4:1-19.
21. Zanussi, S., C. Simonelli, M. D'Andrea, C. Caffau, M. Clerici, U. Tirelli, and P. De Paoli. 1996. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin. Exp. Immunol. 105:220-224.
22. Zanussi, S., C. Simonelli, M. D'Andrea, M. Comar, E. Bidoli, M. Giacca, U. Tirelli, E. Vaccher, and P. De Paoli. 1996. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res. Hum. Retroviruses. 12:1703-1707.
23. Comar, M., C. Simonelli, S. Zanussi, P. De Paoli, E. Vaccher, U. Tirelli, and M. Giacca. 1997. Dynamics of HIV mRNA expression in patients with long-term non-progressive HIV-1 infection. J. Clin. Invest. 100:893-903.
24. Armitage, P., and G. Berry. 1987. Statistical methods in medical research. Blackwell Scientific Publications, Oxford, UK.
25. Helbert, M.R., J. L'age-Stehr, and N.A. Mitchison. 1993. Antigen presentation, loss of immunological memory and AIDS. Immunol. Today. 14:340-344.
26. Benito, J.B., J.M. Zabay, J. Gil, M. Bermejo, A. Escudero, E. Sanchez, and E. Fernandez-Cruz. 1997. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR and CD25 antigens. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 14:128-135.
27. Zanussi, S., M. D'Andrea, C. Simonelli, U. Tirelli, and P. De Paoli. 1996. Serum levels of RANTES and MIP-1 in HIV-positive long-term survivors and progressor patients. AIDS (Lond.). 10:1450-1451.
28. Paxton, W.A., S.R. Martin, D. Tse, T.R. O'Brien, J. Skurick, N.L. Van Devanter, N. Padian, J.F. Braun, D.P. Dotler, S.N. Wolinsky, and R.A. Koup. 1996. Relative resistence to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat. Med. 2:412-417.
29. Urbu, W.J., R.G. Steis, D.L. Longo, W.C. Kopp, A.E. Maluish, L. Marcon, D.L. Nelson, H.C. Stevenson, and J.W. Clark. 1990. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 50: 185-192.
30. Schaafsma, M.R., J.H.F. Falkenburg, J.E. Landegent, N. Duinkerken, S. Osanto, P. Ralph, K. Kaushansky, G. Wagemaker, J. Van Damme, R. Willemze, and W.E. Fibbe. 1991. In vivo production of interleukin-5. granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood. 78:1981-1987.
31. Davey, R.T. Jr., D.G. Chaitt, S.C. Piscitelli, M. Wells, J.A. Kovacs, R.E. Walker, J. Falloon, M.A. Polis, J.A. Metcalf, H. Masur, et al. 1997. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175:781-789.
32. Kovacs, J.A., M. Baseler, R.J. Dewar, S. Vogel, R.T. Davey, J. Falloon, M.A. Polis, R.E. Walker, R. Stevens, N.P. Salzman, J.A. Metcalf, H. Masur, and H.C. Lane. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332:567-575.
33. Vanham, G., L. Kestens, I. De Meester, J. Vingerhoets, G. Penne, G. Vanhoof, S. Scharpè, H. Heyligen, E. Bosmans, J.L. Ceuppens, and P. Gigase. 1993. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J. Acquired Immune Defic. Syndr. 6:749-757.
34. Meyaard, L., S.A. Otto, B. Hooibrink, and F. Miedema. 1994. Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells. J. Clin. Invest. 94:1947-1952.
35. Bell, E.B., and S.M. Sparshott. 1990. Interconversion of CD45R subsets of CD4 T cells in vivo. Nature. 348:163-166.
36. Roth, M.D. 1994. Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. J. Exp. Med. 179:857-864.
37. Janossy, G., N. Borthwick, R. Lomnitzer, E. Medina, S.B. Squire, A.N. Phillips, M. Lipman, M.A. Johnson, C. Lee, and M. Bofill. 1993. Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineages. AIDS (Lond.). 7:613-624.
38. Weng, N., B.L. Levine, C.H. June, and R.J. Rhodes. 1995. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. USA. 92:11091-11094.
39. Woods, T.C, B.D. Roberts, S.T. Butera, and T.M. Folks. 1997. Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood. 89:1635-1641.
40. Ben-Sasson, S.Z., G. Le Gros, D.H. Conrad, F.D. Finkelman, and W.A. Paul. 1990. IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. J. Immunol. 145:1127-1136.
41. Schell-Toeller, D., E. Richter, K.M. Toellner, N. Reiling, H.H. Wacker, H.D. Flad, and J. Gerdes. 1995. CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-γ. Lab. Invest. 73: 685-691.
42. Sakito, S., Y. Ueki, K. Eguchi, Y. Kawabe, and S. Nagataki. 1995. Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon and tumor necrosis factor with the characteristics of peripheral blood mononuclear cells. Rheumatol. Int. 15:31-37.
43. Pizzolo, G., F. Vinante, L. Morosato, G. Nadali, M. Chilosi, G. Gandini, A. Sinicco, R. Raiteri, G. Semenzato, H. Stein, and G. Perona. 1994. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS (Lond). 8: 741-745.
44. Romagnani., S. 1996. TH1 and TH2 in human diseases. Clin. Immunol. Immunopathol. 80:225-235.
45. Cook, D.N., M.A. Beck, T.M. Coffman, S.L. Kirby, J.F. Sheridan, I.B. Pragnell, and O. Smithies. 1995. Requirement of MIP1 for an inflammatory response to viral infection. Science. 269:1583-1585.